Citation Impact
Citing Papers
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
Oral cavity and oropharyngeal squamous cell carcinoma—an update
2015 Standout
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Molecular imaging in drug development
2008 Standout
Guidelines on Urolithiasis<footref rid="foot01"><sup>1</sup></footref>
2001 Standout
Molecular imaging in living subjects: seeing fundamental biological processes in a new light
2003 Standout
PET in the management of locally advanced and metastatic NSCLC
2015
PET as a potential tool for imaging molecular mechanisms of oncology in man
2001
Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: A prospective study
2006
Taking advantage of luminescent lanthanide ions
2005 Standout
FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy
2004
18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation
2011
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma
2004
Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis
2007
Primary Tumor Standardized Uptake Value Measured on Fluorodeoxyglucose Positron Emission Tomography Is of Prognostic Value for Survival in Non-small Cell Lung Cancer: Update of a Systematic Review and Meta-Analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project
2010
Double-Phase Tc-99m Sestamibi Scintigraphy in the Preoperative Location of Lesions Causing Hyperparathyroidism
1998
Sentinel Lymph Node Biopsy for Papillary Thyroid Cancer: 12 Years of Experience at a Single Institution
2010
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
2018 Standout
Synthesis of [18F]RGD-K5 by catalyzed [3+2] cycloaddition for imaging integrin αvβ3 expression in vivo
2013 StandoutNobel
Meta-DiSc: a software for meta-analysis of test accuracy data
2006 Standout
Imaging of the lymphatic system: new horizons
2006
FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease
2006
Tissue‐specific differences in 2‐fluoro‐2‐deoxyglucose metabolism beyond FDG‐6‐P: a 19F NMR spectroscopy study in the rat
2003
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients
2006
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
2005
The role of coordination chemistry in the development of target-specific radiopharmaceuticals
2004
Development and External Validation of Prognostic Model for 2-Year Survival of Non–Small-Cell Lung Cancer Patients Treated With Chemoradiotherapy
2008
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
2002 Standout
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1
2000
Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma
2004
Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers
2006
Recent progress in fluorine-18 labelled peptide radiopharmaceuticals
2001
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
2005
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Radiomics: Extracting more information from medical images using advanced feature analysis
2012 Standout
Sodium Iodide Symporter in Health and Disease
2001
Should ‘low‐risk’ thyroid cancer patients with residual thyroglobulin be re‐treated with iodine 131?
2006
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1
2006 Standout
Minimizing Cost and Maximizing Success in the Preoperative Localization Strategy for Primary Hyperparathyroidism
2014
FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma
2008
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides
2008
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
2005
Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
2006 Standout
Imaging in staging of malignant lymphoma: a systematic review
2007
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
2005
Cost Effectiveness of Positron Emission Tomography in Patients With Hodgkin's Lymphoma in Unconfirmed Complete Remission or Partial Remission After First-Line Therapy
2010
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Clearance Properties of Nano-Sized Particles and Molecules as Imaging Agents: Considerations and Caveats
2008 Standout
Bifunctional Chelators for Therapeutic Lanthanide Radiopharmaceuticals
2000
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.
2006
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Revised Response Criteria for Malignant Lymphoma
2007 Standout
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
2006 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome
2005
Early-Stage Imaging of Nanocarrier-Enhanced Chemotherapy Response in Living Subjects by Scalable Photoacoustic Microscopy
2014
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings
2003
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.
2002 Standout
Guidelines for the management of thyroid cancer
2014 Standout
Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology
2007 Standout
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
2009
CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment: A Quantitative Analysis Correlated with FDG PET Findings
2004
Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
2007
Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline
2014 Standout
The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism
2016 Standout
Works of M. J. OʼDoherty being referenced
FDG-PET maximum standardised uptake value is associated with variation in survival: Analysis of 498 lung cancer patients
2006
99Tcm sestamibi — a new agent for parathyroid imaging
1989
Radiation dose rates from patients undergoing positron emission tomography: implications for technologists and waiting areas
2000
Reactor-produced radioisotopes from ORNL for bone pain palliation
1998
Correlation between Ki-67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis
2012
Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma
1998
The role of sentinel lymph node biopsy in patients with differentiated thyroid carcinoma
2006
18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT
2000
Positron Emission Tomography in the Management of Lymphomas
2002
Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas
1998
Rapid synthesis and biodistribution of [18F]-labelled linear peptides
2000
The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma
2000
PET in oncology I - lung, breast, soft tissue sarcoma
2000
63. RCP guidelines on radiation protection following radio-iodine therapy for thyrotoxicosis
1996